Company
Enanta Pharmaceuticals, Inc.
Headquarters: Watertown, MA, United States
Employees: 155
CEO: Dr. Jay R. Luly
Market Cap
$168.7 Million
USD as of July 1, 2025
Enanta Pharmaceuticals, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Financials
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $73.6 M |
| EBITDA | $-139,578,000 |
| Gross Profit TTM | $0 |
| Profit Margin | -187.77% |
| Operating Margin | -193.78% |
| Quarterly Revenue Growth | -23.70% |
Stocks & Indices
Enanta Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: NASDAQ: ENTA wb_incandescent
Stock: FSX: 9EP wb_incandescent